• Explore /
  • Poster
  • / Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin.

Phase II study of nanoliposomal irinotecan (nal-IRI) with 5-fluorouracil (5-FU)/folinic acid (FA) in refractory advanced high-grade neuroendocrine cancer (HG-NEC) of gastroenteropancreatic (GEP) or unknown origin.

Abstract Poster

Authors

Medhavi Gupta

Medhavi Gupta

Roswell Park Cancer Institute, Dept. of Medicine, Buffalo, NY

Medhavi Gupta , Minsig Choi , Robert A. Ramirez , Kristopher Attwood , Sarbajit Mukherjee , Renuka V. Iyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03736720

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS636)

Abstract #

TPS636

Poster Bd #

P19

Abstract Disclosures

Similar Posters

First Author: Do-Youn Oh

First Author: Benjamin Adam Weinberg

First Author: Zhichao Jiang

First Author: Manojkumar Bupathi